Nigeria Set to Introduce Revolutionary HIV Prevention Drug in 2026
The Federal Government has officially announced that consignments of Lenacapavir, a groundbreaking new drug for HIV prevention, are scheduled to arrive in Nigeria in March 2026. This significant development was disclosed by the National Agency for the Control of AIDS (NACA) in a detailed statement released on Monday, March 2, 2026.
Advancing Preparations for Lenacapavir Rollout
NACA confirmed that it is actively advancing comprehensive preparations for the introduction and nationwide rollout of Lenacapavir (LEN) as a pre-exposure prophylaxis (PrEP) option. Lenacapavir represents a major leap forward in HIV prevention as a long-acting injectable PrEP that requires administration only twice per year, offering a more convenient alternative to daily oral medications.
In extensive clinical trials, Lenacapavir demonstrated exceptional efficacy, significantly reducing the risk of HIV infection and providing nearly total protection against the virus. The Government of Nigeria emphasized its commitment to strengthening HIV prevention efforts and accelerating progress toward epidemic control through this initiative.
Structured Implementation Strategy
According to NACA, coordinated efforts are currently underway to ensure a structured and quality-assured rollout of Lenacapavir in priority states across the country. Nigeria is on track for a phased introduction of LEN PrEP, supported by:
- Full regulatory approval
- Comprehensive system preparedness plans
- Extensively trained healthcare personnel
- Robust community engagement strategies
State-Level Readiness Assessments
NACA has completed thorough landscape and readiness assessments in ten key states to evaluate service delivery capacity and identify specific implementation needs. The assessed states include:
- Akwa Ibom
- Anambra
- Benue
- Cross River
- Ebonyi
- Federal Capital Territory (FCT)
- Gombe
- Kano
- Kwara
- Lagos
Capacity Building and Awareness Campaigns
To ensure successful implementation, NACA conducted a national training of trainers in Abuja, followed by step-down training sessions for healthcare workers in the selected implementation states. Additionally, the agency has developed comprehensive information, education, and communication (IEC) materials to support awareness creation and public education ahead of the official drug rollout in March 2026.
The arrival of Lenacapavir marks a pivotal moment in Nigeria's ongoing battle against HIV/AIDS, offering a promising new tool in the national prevention arsenal that could dramatically impact infection rates and improve public health outcomes nationwide.
